β-Cyclodextrin/epoxysuccinyl peptide conjugates: A new drug targeting system for tumor cells

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 7, 2000, Pages 677-680

  Schaschke, Norbert ^a   Assfalg Machleidt, Irmgard ^b   Machleidt, Werner ^b   Laßleben, Thomas ^c   Sommerhoff, Christian P ^c   Moroder, Luis ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; CATHEPSIN B; DRUG CARRIER; METHOTREXATE; PROTEIN INHIBITOR;

ARTICLE; CANCER INVASION; COMPLEX FORMATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PARTIAL DRUG SYNTHESIS; PROTEIN INTERACTION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; BETA-CYCLODEXTRINS; CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPOXY COMPOUNDS; HUMANS; INCLUSION BODIES; METHOTREXATE; PEPTIDES; TUMOR CELLS, CULTURED;

EID: 0034599531     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00078-0     Document Type: Article

References (19)

1. Sloane, B. F. Semin. Cancer Biol. 1990, 1, 137.
2. Elliott, E.; Sloane, B. F. Perspect. Drug Discov. Design 1996, 6, 12.
3. Panchal, R. G.; Cusack, E.; Cheley, S.; Bayley, H. Nat. Biotechnol 1996, 14, 852.
4. Albers, E.; Müller, B. W. Critical Reviews in Therapeutic Drug Carrier Systems 1995, 12, 311.
5. Djedaïni-Pilard, F.; Désalos, J.; Perly, B. Tetrahedron Lett. 1993, 34, 2457.
6. Hristova-Kazmierski, M. K.; Horan, P.; Davis, P.; Yamamura, H. I.; Kramer, T.; Horvath, R.; Kazmierski, W. M.; Porreca, F.; Hruby, V. J. Bioorg. Med. Chem. Lett. 1993, 3, 831.
7. Schaschke, N.; Fiori, S.; Weyher, E.; Esrieut, C.; Fourmy, D.; Müller, G.; Moroder, L. J. Am. Chem. Soc. 1998, 120, 7030.
8. Attioui, F.; Al-Omar, A.; Leray, E.; Parrot-Lopez, H.; Finance, C.; Bonaly, R. Biol. Cell. 1994, 82, 161.
9. Schaschke, N.; Musiol, H.-J.; Assfalg-Machleidt, I.; Machleidt, W.; Rudolph-Böhner, S.; Moroder, L. FEBS Lett. 1996, 391, 297.
10. Schaschke, N.; Assfalg-Machleidt, I.; Machleidt, W.; Moroder, L. FEBS Lett. 1998, 421, 80.
11. Musil, D.; Zucic, D.; Turk, D.; Mayr, I.; Huber, R.; Popovic, T.; Turk, V.; Towatari, T.; Katunuma, N.; Bode, W. EMBO J. 1991, 10, 2321.
12. Coste, J.; Le-Nguyen, D.; Castro, B. Tetrahedron Lett. 1990, 31, 205.
13. 44: 1797.7.
14. Singh, U. V.; Aithal, K. S.; Udupa, N. Pharm. Sci. 1997, 3, 573.
15. The ESI-MS of an equimolar mixture of methotrexate and conjugate 7 (c (methotrexate)=c (conjugate 7)=0.1 mM) in 1% aqueous trifluoroacetic acid was recorded on a PE SCIEX API 165.
16. The spectra of methotrexate (c=10 μM in 50 mM phosphate buffer, pH=8.0) at increasing concentrations of the conjugate 7 (c=0, 0.1, 0.5, 1.0, and 2.0 mM) were recorded on a Perkin-Elmer UV-vis spectrometer Lambda 19 using 1 cm cells at 25°C.
17. 10
18. Fujishima, A.; Imai, Y.; Nomura, T.; Fujisawa, Y.; Yamamoto, Y.; Sugawara, T. FEBS Lett. 1997, 407, 761.
19. 2. After washing the cells three times with serum-free medium (SFM) at 37°C, they were incubated at 37°C with 300 μL of the inhibitor solution (SFM containing 1% DMSO) for 30 min. Then the cells were washed five times with PBS-buffer at room temperature followed by treatment with 200 μL lysis-buffer (0.5% Triton X-100, 50 mM sodium acetate pH 5.5, 2 mM EDTA) at room temperature for 30 min. The residual cathepsin B-activity was determined in the lysates with the fluorogenic substrate Z-Phe-Arg-NHMec and subsequent inhibition by inhibitor 1 (50 nM).